|
⚲
|
| Keyboard |
| Matrix Capital Management Company LP
✚
|
|
|---|---|
| CRD # | 160066 |
| SEC # | 801-73612 |
| CIK # | 0001906866, 0001410830 |
| AUM | 2,323.7 M (2026-03-31) |
| Employees | 7 (57% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 603-956-9151 |
| Address | 3 Pleasant Street Portsmouth, NH 03801 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($B) |
|---|
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| AURA Biosciences Inc | 0.0 | ||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| PE | Ayurmaya Capital Management Fund LP | [2021-12-15] | 655.0 M | 756.9 M |
| Filed 2021-12-15 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose | ||||
| HF | Matrix Capital Management Fund II LP | [2012-02-14] | 25.4 M | 46.9 M |
| Filed 2017-03-21 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Minimum $50,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Matrix Capital Management Master Fund LP | [2012-02-14] | 1,327.5 M | 1,566.8 M |
| Filed 2025-03-14 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Commission $48,138 · Net Assets Decline to Disclose | ||||
| HF | Matrix Capital Management Restricted Investment Fund LP | 2012-02-14 | 10.4 M | |
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 4 | 2.3 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 4 | 2.3 |
| By Discretionary | ||
| Discretionary | 4 | 2.3 |
| Non-Discretionary | 0 | 0.0 |
| Total | 4 | 2.3 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.6 | |
| United States Persons | 1.7 | |
| Total | 4 | 2.3 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Laren Gillespie | Director | 119 | 24 | |
| Lisa Alexander | Director | 75 | 17 | |
| Richard Ruffer | Director | 422 | 15 | |
| Christine Fletcher | Director | 71 | 13 | |
| Alison Martinson | Director | 38 | 13 | |
| Gregory Brown | Director | 31 | 3 | |
| David Goel | Director, Executive Officer | 13 | 2 | |
| Matrix General Partner LP | Executive Officer | 2 | 2 | |
| Matrix General Partner LLC | Executive Officer | 2 | 2 | |
| Ayurmaya General Partner LLC | Executive Officer | 1 | 1 | |
| View All | ||||
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001410830] | |
| 3 | [0001410830] | |
| 4 | [0001410830] | |
| SC 13D | [0001410830] | |
| SC 13G | [0001410830] | |
| 13F-HR | [0001906866] |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $1.5B |
| Serves | Institutional |
| Fund Types | Hedge Fund, Private Equity |
| LEI | 549300CAYJ90YENRRB21 |
| Form 3/4/5 Subject | 2011 - 2026 |
|---|---|
| Matrix Capital Management Company LP | |
| Aura Biosciences Inc | |
| GOEL David E | |
| Zentalis Pharmaceuticals Inc | |
| Adaptive Biotechnologies Corp |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Zentalis Pharmaceuticals Inc ZNTL
Common Stock, par value $0.001 per share
|
2025-12-15 | Sell | 7,500,000 | $1.33 | 9,975,000 |
|
Aura Biosciences Inc AURA
Common Stock, par value $0.00001 per share (Common Stock)
|
2023-11-09 | Buy | 1,560,000 | $9.00 | 14,040,000 |
|
Zentalis Pharmaceuticals Inc ZNTL
Common Stock, par value $0.001 per share
|
2023-06-20 | Buy | 4,760,000 | $22.66 | 107,861,600 |
|
Aura Biosciences Inc AURA
"Common Stock, par value $0.00001 per share (""Common Stock"")"
|
2022-12-05 | Buy | 1,250,000 | $12.00 | 15,000,000 |
|
Aura Biosciences Inc AURA
Common Stock
|
2021-11-02 | Buy | 1,785,000 | $14.00 | 24,990,000 |
|
Aura Biosciences Inc AURA
Series E Convertible Preferred Stock · derivative
|
2021-11-02 | Conversion | 2,327,870 | $0.00 | |
|
Aura Biosciences Inc AURA
"Common Stock, par value $0.00001 per share (""Common Stock"")"
|
2021-11-02 | Conversion | 2,327,870 | ||
|
Adaptive Biotechnologies Corp ADPT
Common Stock
|
2021-03-10 | Sell | 30,268 | $42.38 | 1,282,758 |
|
Adaptive Biotechnologies Corp ADPT
Common Stock
|
2021-03-10 | Sell | 25,732 | $41.47 | 1,067,106 |
|
Adaptive Biotechnologies Corp ADPT
Common Stock
|
2021-03-09 | Sell | 34,302 | $41.16 | 1,411,870 |
|
Adaptive Biotechnologies Corp ADPT
Common Stock
|
2021-03-09 | Sell | 215,698 | $40.42 | 8,718,513 |
|
Adaptive Biotechnologies Corp ADPT
Common Stock
|
2021-03-08 | Sell | 71,194 | $41.21 | 2,933,905 |
|
Adaptive Biotechnologies Corp ADPT
Common Stock
|
2021-03-08 | Sell | 234,295 | $38.22 | 8,954,755 |
|
Adaptive Biotechnologies Corp ADPT
Common Stock
|
2021-03-08 | Sell | 75,000 | $39.22 | 2,941,500 |
|
Adaptive Biotechnologies Corp ADPT
Common Stock
|
2021-03-08 | Sell | 33,600 | $39.97 | 1,342,992 |
|
Adaptive Biotechnologies Corp ADPT
Common Stock
|
2021-03-08 | Sell | 85,911 | $41.62 | 3,575,616 |
|
Adaptive Biotechnologies Corp ADPT
Common Stock
|
2020-07-20 | Sell | 2,000,000 | $40.00 | 80,000,000 |
|
Adaptive Biotechnologies Corp ADPT
Common Stock
|
2020-01-24 | Conversion | 2,217,101 | $26.50 | 58,753,176 |
|
Adaptive Biotechnologies Corp ADPT
Common Stock
|
2019-07-01 | Conversion | 84,359 | ||
|
Adaptive Biotechnologies Corp ADPT
Series E-1 Convertible Preferred Stock · derivative
|
2019-07-01 | Conversion | 5,893,716 | $0.00 | |
| showing 20 of 26 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
Oxford Finance Advisors LLC
✚
|
VA | 2,406.9 M |
|
Irenic Capital Management LP
✚
|
NY | 2,398.7 M |
|
Broadriver Asset Management LP
✚
|
NY | 2,342.3 M |
|
Tiptree Advisors LLC
✚
|
NY | 2,310.8 M |
|
SageView Capital LP
✚
|
CT | 2,307.2 M |
|
Varadero Capital LP
✚
|
NY | 2,292.2 M |
|
Waratah Capital Advisors Ltd
✚
|
2,271.0 M | |
|
Coliseum Capital Management LLC
✚
|
CT | 2,269.4 M |
|
Teng Yue Partners LP
✚
|
NY | 2,247.5 M |
|
Mason Capital Management LLC
✚
|
NY | 2,237.5 M |